July 3, 2026 | Shanghai
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend the AIBC2026: Artificial Intelligence for BioPharma Conference in Shanghai on July 3. Dr. Ren will deliver a keynote speech titled "Revolutionizing Drug Discovery Paradigms with Generative AI" from 13:40 to 14:05 PM, sharing deep insights into the cutting-edge applications and innovative breakthroughs of AI in modern pharmaceutical R&D.
From algorithmic innovation to clinical validation, generative AI is propelling drug R&D into a highly efficient, "end-to-end" new era. As an industry pioneer advancing generative AI-discovered drugs into clinical trials, Insilico Medicine has accumulated extensive hands-on experience in AI-driven drug discovery. In this presentation, Dr. Ren will deconstruct an end-to-end generative AI drug R&D system encompassing biology, medicinal chemistry, and clinical medicine. By sharing the development journeys of multiple AI-native drug candidates currently in clinical stages, his speech will provide an in-depth analysis of the core mechanisms and latest breakthroughs of generative AI in molecular design, multi-target synergy, and improving clinical translation success rates.
Artificial Intelligence for BioPharma Conference (AIBC) is a premier industry event in China's cross-disciplinary field of "AI + Biopharma." Having successfully concluded five sessions, the conference has not only witnessed profound transformations driven by AI in key sectors such as drug discovery, pharmaceutical R&D, life sciences, and synthetic biology, but also continuously pushed AI-driven drug discovery from technical exploration to large-scale industrialization. Today, it serves as a central hub and high-end dialogue platform linking industry, academia, research, and investment to foster ecosystem collaboration. The conference will bring together top global scientists, entrepreneurs, investors, policymakers, and cross-sector innovators to systematically map out the latest breakthroughs and future trends of AI across the entire biopharma value chain. Through deep exchanges addressing technological frontiers, industry pain points, and ecosystem partnerships, attendees will jointly blueprint a new AI revolution stretching from laboratory R&D to commercialization.
As an AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development through its advanced AI and automation platform, setting a new standard for the industry. While traditional early-stage drug discovery typically takes 2.5 to 4 years, Insilico has consistently reached preclinical candidate (PCC) nomination in an average of just 12 to 18 months, with only 60 to 200 molecules synthesized and tested per program. Since 2021, the company has nominated 31 PCCs, 13 of which have received IND approval or clearance.
While expanding the practical applications of its technology in drug discovery and life science research, Insilico is also continuously enhancing the performance of its AI platform. Drawing on extensive experience and datasets from its training platform, the company has distilled thousands of benchmarks and integrated them into MMAI Gym. Serving as both a “trainer and benchmark” for scientific AI, MMAI Gym enables organizations to train models for domain-specific reasoning while rigorously evaluating their performance on real-world tasks, advancing the path toward pharma superintelligence. To date, Human Longevity and Liquid AI have collaborated with Insilico, joining as partners of MMAI Gym.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.co